Advertisement

Carcinogenic Drugs: A Model Data-Base for Human Risk Quantification

  • J. Kaldor

Abstract

Many of the drugs used in cancer chemotherapy are themselves carcinogenic. However, they differ from other carcinogens, in that humans are intentionally exposed to them at high, carefully measured doses. Studies of second cancers following chemotherapy have as their primary goal the reduction of long-term risk through suitable modification of therapy. However, they can also provide unique quantitative information on human carcinogenesis. We discuss the information available on various aspects of chemotherapy-induced leukemia, including dose-effect and temporal relationships, and suggest ways in which statistical analyses could be extended. Further topics considered include the comparative carcinogenicity of chemotherapeutic agents and radiation, and other endpoints related to carcinogenicity which may usefully be studied in treated patients.

Keywords

Cancer Risk Acute Leukemia Excess Relative Risk Human Carcinogen Human Carcinogenesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    B.C. ALLEN, K.S. CRUMP and A.M. SHIPP. Correlation between carcinogenic potency of chemicals in animals and humans. Risk Analysis, 8 (1988), pp. 531–544.CrossRefGoogle Scholar
  2. 2.
    P. ARMITAGE and R. DOLL. The age distribution of cancer and a multistage theory of carcinogenesis. British Journal of Cancer, 8 (1959), pp. 1–12.CrossRefGoogle Scholar
  3. 3.
    J.M. BENNETT, D. CATOVSKY, M.T. DANIEL et al. The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. British Journal of Haematology, 47 (1981), pp. 553–561.CrossRefGoogle Scholar
  4. 4.
    D.W. BLAYNEY, D.L. LONGO, R.C. YOUNG, M.H. GREENE, S.M. HUBBARD, M.G. POSTAL et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin’s disease. New England Journal of Medicine, 316 (1987), pp. 710–714.CrossRefGoogle Scholar
  5. 5.
    J.D. BOICE Jr., M.H. GREENE, J.Y. KILLEN Jr., S.S. ELLENBERG and J.G. FRAUMENI Jr. Leukemia after adjuvant chemotherapy with semustine (methyl-CCNU). Evidence of a dose-response effect. New England Journal of Medicine, 314 (1986), pp. 119–120.CrossRefGoogle Scholar
  6. 6.
    J.D. BOICE, M. BLETTNER, R.A. KLEINERMAN et al. Radiation dose and leukaemia risk in patients treated for cancer of the cervix. Journal of the National Cancer Institute, 74 (1987), pp. 1295–1311.Google Scholar
  7. 7.
    N.E. BRESLOW and N.E. DAY. Statistical Methods in Cancer Research, Volume II, The Design and Analysis of Cohort Studies (IARC Scientific Publications No. 82), Lyon, (1987) International Agency for Research on Cancer.Google Scholar
  8. 8.
    J. CUZICK, S. ERSKINE, D. EDELMÀn and D.A.G. GALTON. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. British Journal of Cancer, 55 (1987), pp. 523–529.CrossRefGoogle Scholar
  9. 9.
    N.E. DAY and C.C. BROWN. Multistage models and the primary prevention of cancer. Journal of the National Cancer Institute, 64 (1980), pp. 977–989.Google Scholar
  10. 10.
    L. EHRENBERG, E. MOUSTÀCCHI, S. OSTERMAN-GOLKAR. Dosimetry of genotoxic agents and dose-response relationships and their effects. Mutation Research, 123 (1983), pp. 121–182.Google Scholar
  11. 11.
    L. GOLD, C. SAWYER, R. MAGAW, G. BACKMAN, M. DE VECIANA, R. LEVINSON, N. HOOPER, W. HAVENDER, L. BERSTEIN, R. PETO, M. PIKE AND B. AMES. A carcinogenic potency data base of the standardized results of animal bioassays. Environmental Health Perspectives, 58 (1984), pp. 9–319.CrossRefGoogle Scholar
  12. 12.
    M.H. GREENE, E.L. HARRIS, D.M. GERESHENSON, G.D. MALKASIAN, L.J. MELTON, A.J. DEMBO et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Annals of Internal Medicine, 105 (1986), pp. 360–367.Google Scholar
  13. 13.
    J.F. HAAS, B. KITELMAN, W.H. MEHNERT, W. STANECZEK, M. MOHNER, J. KALDOr and N.E. DAY. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. British Journal of Cancer, 55 (1987), pp. 213–218.CrossRefGoogle Scholar
  14. 14.
    IARC. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Supplement 7 (1987), International Agency for Research on Cancer, Lyon, France.Google Scholar
  15. 15.
    J. KALDOR, N.E. DAY, P. BAND, N.W. CHOI, E.A. CLARKE, M.P. COLEMAN et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin’s disease: An international collaborative study among cancer registries. International Journal of Cancer, 39 (1987), pp. 571–585.CrossRefGoogle Scholar
  16. 16.
    J. KALDOR, N.E. DAY and H. HEMMINKI. Quantifying the carcinogenicity of antineoplastic drugs. European Journal of Cancer Clinical Oncology, 24 (1988), pp. 703–711.CrossRefGoogle Scholar
  17. 17.
    J. KALDOR and N.E. DAY. Estimation of temporal effects in treatment-induced second cancer. Statistics in Medicine, 8 (1989) (in press).Google Scholar
  18. 18.
    S.H. MOOLGAVKAR and A.G. KNUDSON Jr. Mutation and Cancer: A model for human carcinogenesis. Journal of the National Cancer Institute, 66 (1981), pp. 1037–1051.Google Scholar
  19. 19.
    CS. MUIR, J. WATERHOUSE, T. MACK, J. POWELL and S. WHELAN. Cancer Incidence in Five Continents, Volume V. (1987) IARC Scientific Publications No. 88.Google Scholar
  20. 20.
    J.D. ROWLEY, H.M. GOLOMB and J.W. VARDIMAN. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood, 58 (1981), pp. 759–767.Google Scholar
  21. 21.
    D. SCHMAHL and H. OSSWALD. Experimental studies on the carcinogenic effect of cancer chemotherapeutic agents and immunosuppression. Arzneimittelforschung, 20 (1970), pp. 1461–1467.Google Scholar
  22. 22.
    D.C. THOMAS. Statistical methods for analyzing effects of temporal patterns of exposure on cancer risks. Scandinavian Journal of Work and Environmental Health, 9 (1983), pp. 353–366.CrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1990

Authors and Affiliations

  • J. Kaldor

There are no affiliations available

Personalised recommendations